4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-009019
Director sold 13,278 shares at $19.16 ($254,462)
- Director acquired 13,278 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ballal Rahul D. Director | 2024-03-20 | Option exercise 10b5-1 | +13,278 | $5.52 | $73,295 | 35,619 | D |
| Ballal Rahul D. Director | 2024-03-20 | Sale 10b5-1 | −13,278 | $19.16 | $254,462 | 22,341 | D |
| Derivatives | |||||||
| Ballal Rahul D. Director | 2024-03-20 | Option exercise · Stock Option (right to buy) 10b5-1 | −13,278 | 19,571 | D | ||
| Open-market sales · 13,278 sh · avg $19.16 · $254,462 | |||||||
Loading xslF345X05/form4-03222024_110316.xml…